Circulating Th17, Th22, and Th1 Cells Are Elevated in the Guillain-Barré Syndrome and Downregulated by IVIg Treatments

Table 1

Clinical survey of the patients with GBS.

Number	Sex	Age (years)	Previous infections	Electrophysiologic findings	GDSs at acute/plateau phases	IVIg
1	Female	51	None	Axonal	3/3	No
2	Male	61	None	Demy.	4/3	Yes
3	Male	39	None	Axonal	5/4	Yes
4	Female	19	None	Demy.	5/4	Yes
5	Female	40	URTI	Demy.	2/2	Yes
6	Male	37	GI + URTI	Axonal	3/3	No
7	Male	43	None	Demy.	3/2	Yes
8	Female	17	None	Axonal	5/3	Yes
9	Female	48	URTI	Demy.	2/2	Yes
10	Male	46	URTI	Axonal	2/1	No
11	Male	48	GI	Axonal	2/2	Yes
12	Male	46	None	Demy.	3/3	Yes
13	Female	51	URTI	Demy.	2/1	Yes
14	Male	28	GI	Demy.	3/3	Yes
15	Male	37	GI	Axonal	2/2	Yes
16	Male	18	GI	Axonal	5/3	Yes
17	Male	35	GI	Demy.	3/2	Yes
18	Male	53	URTI	Demy.	4/3	Yes
19	Female	63	URTI	Demy.	3/1	Yes
20	Male	40	GI + URTI	Demy.	4/2	Yes
21	Male	27	GI	Axonal	5/3	Yes
22	Male	49	None	Axonal	2/2	Yes
23	Female	61	None	Axonal	1/1	Yes
24	Male	33	GI	Axonal	1/0	Yes
25	Male	44	GI	Demy.	5/3	Yes
26	Male	46	None	Axonal	3/3	No
27	Male	54	None	Axonal	1/1	No
28	Male	38	GI	Axonal	2/0	Yes
29	Female	29	GI	Axonal	3/1	Yes

GI: gastrointestinal infections; URTI: upper respiratory tract infections; demy.: primary demyelination; axonal: primary axonal injury; IVIg: intravenous immunoglobulin treatments.